Beam Therapeutics (BEAM) closed out FY 2025 with Q4 revenue of US$114.1 million and basic EPS of US$2.37, alongside net income of US$244.3 million, which sits against trailing twelve month revenue of US$139.7 million and a loss of US$80.0 million on basic EPS of US$0.81. Over recent quarters, the company has seen revenue move from US$7.5 million in Q1 2025 to US$9.7 million in Q3 2025 and then to US$114.1 million in Q4. Basic EPS shifted from losses of US$1.24, US$1.00 and US$1.10 in the first three quarters of 2025 to a profit of US$2.37 in Q4, setting up a results season where investors will be weighing revenue momentum against still thin margins and a mixed earnings profile.

See our full analysis for Beam Therapeutics.

With the latest figures on the table, the next step is to set these results against the prevailing Beam Therapeutics narratives to see which storylines the numbers support and which they call into question.

TTM loss of US$80 million keeps profitability out of reach

• On a trailing twelve month basis, Beam reported total revenue of US$139.7 million and a net loss of US$80.0 million, with TTM basic EPS at a loss of US$0.81 despite the profitable Q4.
• Bears point out that earnings are forecast to decline by about 6.9% per year for the next three years even though losses have narrowed by roughly 4.6% per year over the past five years.
  • This combination of a recent US$80.0 million loss and expectations for further earnings declines lines up with the cautious view that profitability is still some way off even after a strong Q4.
  • At the same time, the five year trend of gradually shrinking losses means the historical record is less severe than a purely bearish focus on continued losses might suggest.

Skeptics warn that a company still posting a TTM loss while earnings are expected to decline can see sentiment turn quickly when expectations shift, so it helps to understand how that cautious view is built in the detailed bear case. 🐻 Beam Therapeutics Bear Case

Revenue forecasts at 36.4% a year set up a growth versus losses trade off

• Analysts are forecasting revenue growth of about 36.4% per year while also expecting the company to remain unprofitable over the next three years, with earnings forecast to decline by around 6.9% per year.
• The bullish narrative leans on a scalable base editing and LNP platform and a broader pipeline to support those growth expectations.
  • Forecast revenue growth of 36.4% a year aligns with the optimistic view that a modular platform and expanding programs can grow the top line faster than development spending.
  • However, the same forecasts that keep the company unprofitable for at least three years show why even strong revenue projections do not automatically translate into earnings improvement.

Supporters argue that if Beam can turn forecast revenue growth into better margins over time, the long run story may look very different from the current loss making picture, which is exactly what the bullish case tries to map out. 🐂 Beam Therapeutics Bull Case

P/S of 23.2x sits between peers and wider biotech

• The stock trades on a P/S ratio of 23.2x, which is lower than the peer average of 32.7x but higher than the broader US Biotechs industry average of 10.8x, against a current share price of US$32.34 and an analyst consensus price target of US$51.20.
• Consensus narrative highlights both the revenue opportunity in genetic medicines and the drag from busulfan risks, competition and ongoing funding needs.
  • The P/S level below closer peers but above the wider industry fits with a view that Beam’s pipeline and technology give it more revenue potential than a typical biotech, while continued losses justify a discount to direct peers.
  • The spread between the current US$32.34 share price and the US$51.20 consensus target shows analysts expect more value than the market is pricing today even though they still do not forecast profitability in the next three years.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Beam Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between a strong Q4 and ongoing losses, it helps to move quickly and test the story against the underlying data yourself. To see both sides laid out clearly, check the 2 key rewards and 2 important warning signs

See What Else Is Out There

Beam is still reporting a trailing twelve month loss of US$80.0 million, with forecasts pointing to ongoing earnings declines despite strong revenue projections.

If you want ideas where the focus is on stability instead of persistent losses, start comparing companies in the 74 resilient stocks with low risk scores to see how different their risk profiles look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.